Following Record-breaking IPO, Hepalink's Claims Attract Skepticism
This article was originally published in PharmAsia News
Following the most expensive IPO to date at RMB 148 per share, Hepalink Pharmaceutical's recent claims of exclusivity for heparin certification have attracted doubt
You may also be interested in...
The US FDA issued only one device-related close-out letter in October.
Seven pharmacies have filed a lawsuit against the FDA claiming the agency exceeded its statutory authority in its final standard memorandum of understanding on interstate compounding and that the MOU will have an adverse impact on compounding pharmacies and patients.
Several experts spoke with Scrip about their take on how the biopharmaceutical industry's efforts to respond to COVID-19 might help industry's image problem.